Direct answer: ketamine is not an established treatment for obsessive-compulsive disorder, and the honest version of the evidence fits in a few paragraphs. This page gives it in full, because "ketamine for OCD" is marketed well ahead of what a handful of very small trials can carry, and because the treatments that actually move OCD (exposure therapy delivered properly, medication dosed properly) are the ones most often missing from a treatment history.
The condition-side view, with the complete guideline ladder from exposure therapy to deep brain stimulation, is in OCD: when standard treatment isn't enough. This page is the method-side summary for people specifically researching ketamine.
TL;DR A small number of very small trials, no approval, no guideline recommendation, no durability data. Rapid short-term reduction in obsessions is a real and interesting research finding; an established treatment it is not. Before anything off-label, the question that changes outcomes is whether you have genuinely had exposure and response prevention and an SSRI at an OCD-appropriate dose (often the licensed maximum, reached gradually) for at least 12 weeks.
The evidence, in full
The controlled evidence for ketamine in OCD remains limited. A small intravenous crossover trial studied 15 unmedicated adults with OCD (not treatment-resistant by protocol). A single subanaesthetic infusion produced rapid reductions in obsessions, and in the first treatment period 4 of 8 participants met response criteria one week after ketamine versus 0 of 7 after saline (Rodriguez et al., 2013). The design caveats are the point: carryover effects limited interpretation, and a proof-of-concept figure in 15 selected people is not a routine-care response rate.
A subsequent intranasal ketamine clinical trial using midazolam as an active comparator was terminated prematurely after only two participants completed the study, preventing meaningful conclusions about efficacy (Rodriguez et al., 2017, reported in Marmureanu et al., 2026). More recently, an intramuscular crossover trial in treatment-resistant OCD used fentanyl as an active control, with 12 randomised and 10 completing: greater short-term Y-BOCS reduction after ketamine, dissociative and cardiovascular effects during sessions, and two discontinuations at the higher dose (Beaglehole et al., 2025). Around these sit small open-label studies with mixed results.
Two recent systematic reviews (Heroiu et al., 2026; Marmureanu et al., 2026) identify three randomised controlled trials, alongside several uncontrolled investigations. Although these studies provide preliminary evidence of rapid anti-obsessional effects, their small samples, heterogeneous administration protocols and limited follow-up prevent firm conclusions about sustained efficacy, optimal dosing or long-term safety.
That is the complete controlled literature. What it supports: a short-term anti-obsessional signal worth researching. What it does not support: durable benefit, an established dosing course, or treating IV, IM and intranasal results as one evidence pool.
No regulator has approved ketamine or esketamine for OCD, and the German S3 guideline contains no ketamine recommendation. Esketamine's EU label (treatment-resistant depression with an oral antidepressant, plus a short-term psychiatric-emergency indication) does not include OCD. Treating a coexisting depression is its own clinical question and not evidence of an anti-OCD effect. The 2026 CANMAT-ICOCS guidelines acknowledge ketamine as a potential consideration in selected, highly treatment-refractory clinical circumstances, while emphasising that the evidence remains limited and its effects may be transient.
What a clinic offering "ketamine for OCD" should provide
Off-label prescribing by a licensed physician is legally accepted; however, the evidence above is what the lawful prescription stands on. A service offering ketamine for OCD should be able to say, concretely:
- which of the trials its protocol resembles
- what happens when a short-lived effect fades
- why exposure and response prevention and guideline medication have been exhausted first
- how it screens and monitors ketamine effects (psychiatric assessment, cardiovascular check, dissociation management, no driving until the next day)
Our choosing a clinic guide covers the generic red flags. For OCD, the specific one is any service that sells infusions without asking what your exposure therapy actually involved.
Established treatment options for OCD
OCD has several well-established, evidence-based treatments.
Cognitive behavioural therapy (CBT) incorporating exposure and response prevention (ERP) is a first-line psychological intervention, recommended by major clinical guidelines, including the German S3 guideline. ERP helps individuals gradually confront feared situations or intrusive thoughts while reducing the compulsive behaviours that maintain the cycle of anxiety and distress.
Pharmacological treatment is another important option. Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed for OCD and may require higher doses and longer treatment periods than those typically used for depression. An adequate trial generally involves approximately 12 weeks of treatment, with dosage adjustments guided by clinical response and tolerability. Where initial treatment is unsuccessful, further options include trying another SSRI, clomipramine, or, in selected cases, antipsychotic augmentation under specialist supervision.
For individuals with severe or treatment-resistant OCD, additional interventions may be considered, including intensive ERP programmes, repetitive transcranial magnetic stimulation (rTMS), and, in exceptional cases, deep brain stimulation (DBS). These approaches differ in their evidence base, availability and suitability, and require individualised specialist assessment.
Our OCD treatment options guide explores these approaches in greater detail. Importantly, while ketamine is an emerging area of research, established OCD treatments currently have a substantially stronger evidence base. Reviewing previous treatment experiences with a qualified clinician may help identify additional options before considering experimental interventions.
Current registered clinical trials
A ketamine OCD trial at the Medical University of Vienna holds an authorised CTIS record (2024-518212-40-00). Registry status lags behind how many people have been enrolled, so current enrollment is a question for the site. For how trials work (phases, placebo, consent, screening), see the trials guide. Your pre-screening can start with the written treatment history that every study and every specialist service asks for first.
Frequently asked questions
Does ketamine cure OCD?
No. The small controlled trials found short-term reductions in symptoms. Nobody has shown durable benefit, and no regulator has approved it for OCD.
Is esketamine (Spravato) an option for OCD?
Not as an OCD treatment. The EU label covers treatment-resistant depression (with an oral antidepressant) and a short-term psychiatric-emergency indication. If you separately have depression that has not responded to adequate treatment, that is its own assessment, mapped in our depression guide.
What should I do before considering any experimental treatments?
Before exploring experimental treatments, it's worth reviewing which evidence-based OCD treatments you've already tried and whether they were delivered at an appropriate intensity and duration. This includes cognitive behavioural therapy with exposure and response prevention (ERP), involving structured exposure exercises, strategies to resist compulsions and practice between sessions, as well as an adequate trial of an SSRI at an appropriate dose, generally assessed over approximately 12 weeks.
Some people with persistent OCD symptoms have not had access to adequately delivered treatment, while others continue to experience significant symptoms despite appropriate care. Reviewing your treatment history with a qualified clinician can help identify whether established options remain worth exploring before considering experimental approaches.
Sources
- Rodriguez et al. (2013) — randomised crossover trial of IV ketamine in OCD
- Rodriguez et al. (2017) — intranasal ketamine vs midazolam in OCD, terminated early
- Beaglehole et al. (2025) — IM ketamine vs fentanyl in treatment-resistant OCD
- Heroiu et al. (2026) — systematic review: ketamine in OCD
- Marmureanu et al. (2026) — systematic review: glutamatergic agents in OCD
- CANMAT-ICOCS (2026) — clinical guidelines for the management of OCD
- AWMF 038-017 — S3-Leitlinie Zwangsstörungen
- NICE CG31 — obsessive-compulsive disorder: treatment
- EMA — Spravato product information (licensed indications)
- CTIS 2024-518212-40-00 — ketamine in OCD, Medical University of Vienna
This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Discuss your options with a licensed clinician who knows your history. If you are in crisis, contact your local emergency number (112 in the EU) or a crisis line immediately.